Skip to main content

EKOS™ Endovascular System

play icon
Video of EKOS™ Endovascular System: How it works
EKOS Ultrasound Guided Catheter directed thrombolysis for the treatment of pulmonary embolism.
The targeted ultrasound waves differentiate this technology, providing accelerated clot dissolution by unwinding the fibrin matrix.
The EKOS catheter is comprised of two parts: the Infusion catheter and the ultrasonic core.
play icon
Video of EKOS™ Endovascular System: How it works
EKOS Ultrasound Guided Catheter directed thrombolysis for the treatment of pulmonary embolism.
The targeted ultrasound waves differentiate this technology, providing accelerated clot dissolution by unwinding the fibrin matrix.
The EKOS catheter is comprised of two parts: the Infusion catheter and the ultrasonic core.
EKOS+: How it works
EKOS Ultrasound-Assisted Catheter-Directed Thrombolysis
The targeted ultrasound waves differentiate this technology, providing accelerated clot dissolution by unwinding the fibrin matrix.
The EKOS catheter is comprised of two parts: the Infusion catheter and the ultrasonic core.

Introducing EKOS+
Same procedure, now 50% more powerful1

With 50% more ultrasound power and 32% more lysis than EKOS1, the new EKOS+ catheter builds on the EKOS legacy. It provides physicians more confidence to efficiently treat PE patients with lower lytic doses.

Key Resources

EKOS indications, safety, and warnings EKOS reimbursement information
Explore Why We EKOS
EKOS system Brochure icon

EKOS system brochure

 Mail icon

Sign-Up for product updates

 3D Icon

View EKOS catheter in 3D

 3D Icon

View EKOS console in 3D

Product description

EKOS is a safe, repeatable and reliable treatment that dissolves thrombus quickly with low lytic, low blood loss and low trauma – resulting in proven long-term outcomes. EKOS leverages the power of targeted ultrasonic waves to thin and separate fibrin strands and accelerates lytic dispersion deeper into the clot. The addition of the new EKOS+ catheter offers the same procedure & clinical workflow, with 50% more ultrasound power.1

Ultrasonic core technology

  • Minimally invasive, 15-minute procedure that is quick to perform
  • Lytic agent: as low as 8 mg tPA used2
  • Ultrasonic waves accelerate clot dissolution by unwinding and thinning fibrin strands to expose more drug receptor sites; acoustic streaming drives the drug deeper into the clot for safe dissolution
Blue circles illustrating target thrombus safety
Target thrombus safety
Blue circles and dots illustrating acoustic pulse acceleration
Acoustic pulse acceleration
Blue dots illustrating superior clot dissolution
Superior clot dissolution

Reimbursement information

The C-Code used for the EKOS™ Endovascular System is C1887 or C1889. C-Codes are used for hospital outpatient device reporting for Medicare and some private payers. Note: Boston Scientific Corporation is not responsible for correct use of codes on submitted claims; this information does not constitute reimbursement or legal advice.
Learn more about EKOS reimbursement
  1.  Bench data on File
  2. Tapson V et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism. JACC: Cardiovascular Interventions 2018; 11(14):1401-1410.

 

Top